Shortcomings of the first-generation proton pump inhibitors

European Journal of Gastroenterology and Hepatology

Volumn 13, Issue SUPPL. 1, 2001, Pages

  Tytgat, G N J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Cytochrome P450; Gastric acid; GORD; Helicobacter pylori; Lansoprazole; Omeprazole; Pantoprazole; Ulcer

Indexed keywords

CAFFEINE; CYCLOSPORIN; CYTOCHROME P450; DIAZEPAM; LANSOPRAZOLE; LIDOCAINE; METOPROLOL; MIDAZOLAM; OMEPRAZOLE; PANTOPRAZOLE; PHENYTOIN; PROPRANOLOL; PROTON PUMP INHIBITOR; QUINIDINE; THEOPHYLLINE; WARFARIN;

CONFERENCE PAPER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; STOMACH ACID SECRETION; STOMACH PH;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; BENZIMIDAZOLES; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; GASTRIC ACID; GASTROESOPHAGEAL REFLUX; HUMANS; OMEPRAZOLE; PROTON PUMPS; SULFOXIDES;

EID: 0034950961     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (48)

1. Proton pump inhibitors: Pharmacology and rationale for use in gastrointestinal disorders
2. Treatment advances in acid secretory disorders: The promise of rapid symptom relief with disease resolution
3. Similarities and differences in the properties of substituted benzimidazoles: A comparison between pantoprazole and related compounds
4. Review article: The pharmacology of rabeprazole
5. Omeprazole
6. + ATPase
7. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression
8. Appropriate acid suppression for optimal healing of duodenal ulcer and gastro-oesophageal reflux disease
9. Review article: The continuing development of proton pump inhibitors with particular reference to pantoprazole
10. Parietal cell protrusions and fundic gland cysts during omeprazole maintenance treatment
11. Lansoprazole and omeprazole in the treatment of acid peptic disorders
12. Omeprazole, Helicobacter pylori status, and alterations in the intragastric milieu facilitating bacterial N-nitrosation
13. Review article: Potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors
14. Omeprazole: An updated review of its pharmacology and therapeutic use in acid-related disorders
15. Omeprazole (20 mg) daily given in the morning or evening: A comparison of effects on gastric acidity, and plasma gastrin and omeprazole concentration
16. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects
17. Variability in individual response to various doses of omeprazole: Implications for antiulcer therapy
18. Acute treatment of duodenal ulcer: Experience with lansoprazole
19. Steady-state intragastric pH-profile after 40 mg pantoprazole: Comparison of morning and evening administration
20. Decreased oral bioavailability of lansoprazole in healthy volunteers when given with a standardised breakfast
21. The effect of food and antacids on lansoprazole absorption and disposition
22. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors
23. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors
24. Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole
25. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily
26. Review article: Cytochrome P450 and the metabolism of proton pump inhibitors - Emphasis on rabeprazole
27. The interaction of proton pump inhibitors with cytochromes P450
28. Clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazole
29. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs
30. Clinical pharmacokinetics of lansoprazole
31. Lack of pantoprazole drug interactions in man
32. Lack of pharmacokinetic interaction between pantoprazole and diclofenac
33. Pantoprazole versus omeprazole: Influence on meal-stimulated gastric acid secretion
34. Acid-inhibitory effects of omeprazole and lansoprazole in Helicobacter pylori-negative healthy subjects
35. The proton-pump inhibitors: Similarities and differences
36. Identification of the characteristics influencing the degree of antisecretory activity of PPIs
37. Pathogenesis and treatment of acid peptic disorders: Comparison of proton pump inhibitors with other antiulcer agents
38. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole
39. Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole
40. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer
41. The Maastricht Consensus Report: Current European concepts in the management of Helicobacter pylori infection
42. Treatment strategies for Helicobacter pylori infection
43. Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans
44. Double blind comparison of omeprazole (40 mg od) versus cimetidine (400 mg qd) in the treatment of symptomatic erosive reflux oesophagitis, assessed endoscopically, histologically and by 24 h pH monitoring
45. Omeprazole causes delay in gastric emptying of digestible meals
46. Parietal cell protrusions in gastric ulcer disease
47. Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status
48. +)-adenosine triphosphatase alpha subunit and its effect on inhibition of rat gastric acid secretion